Alpha Teknova, Inc. Provides Preliminary Revenue Guidance for the Second Quarter Ended June 30, 2024 and Reaffirms Revenue Guidance for the Year 2024
July 09, 2024 at 05:04 pm
Share
Alpha Teknova, Inc. provided preliminary revenue guidance for the second quarter ended June 30, 2024 and reaffirmed revenue guidance for the year 2024. The company expects second quarter 2024 total revenue is in the range of $9.4 to $9.6 million, down 17% to 18% when compared to second quarter 2023.
The company reaffirmed its fiscal 2024 revenue guidance of $35-38 million.
Alpha Teknova, Inc. is a producer of critical reagents for the research, discovery, development, and commercialization of therapies, vaccines, and molecular diagnostics. It offers two primary business lines, which include lab essentials and clinical solutions. It also offers three primary product types: pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. The Company offers its liquid cell culture media and supplements and molecular biology reagents in both of its two product categories; pre-poured media plates are available in its Lab Essentials category only. Its customers include pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostics franchises, and academic and government research institutions developing vaccines and therapies and performing basic research.
ALPHA TEKNOVA, INC. 
